Sepsis, a complex clinical syndrome resulting from a dysregulated immune response to infection, remains a significant global health challenge, with high morbidity and mortality rates. Early identification and risk stratification are essential for improving patient outcomes. This multicenter prospective cohort study evaluates the role of serum lactate dehydrogenase (LDH) and C-reactive protein (CRP) as predictive biomarkers in sepsis. Conducted across three tertiary care hospitals, the study examines the correlation between biomarker levels, sepsis severity, and clinical outcomes, including mortality and ICU length of stay. Results demonstrated that elevated LDH and CRP levels are strongly associated with adverse outcomes, underscoring their potential as cost-effective tools for risk stratification in diverse clinical settings. Incorporating these biomarkers into routine sepsis management protocols may improve early diagnosis, prognostication, and therapeutic decision-making. Further research is warranted to explore their dynamic changes during disease progression and validate findings across broader populations.